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Systemic treatment of hepatocellular carcinoma: why so many failures in the 
development of new drugs? 
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ABSTRACT 
Introduction: The increasing knowledge of the genomic landscape of hepatocellular 
carcinoma (HCC) and the development of molecular targeted therapies are a promising 
background for increasing the number of effective drugs for HCC patients. In recent years, 
many new drugs have been tested as an alternative to sorafenib or after sorafenib failure. 
Areas covered: In this review, our aim is to describe the randomized trials recently 
conducted in HCC patients, in order to understand the main reasons potentially related to 
the failures of many drugs. In addition, we briefly describe the main ongoing trials, that 
could potentially change the scenario of HCC treatment in the next years. 
Expert Commentary: Heterogeneity of study populations, lack of understanding of critical 
drivers of tumor progression, risk of liver toxicity associated with experimental agents, 
flaws in trial design and marginal antitumoral potency can be considered the main reasons 
for failure of phase III clinical trials in HCC. Most ongoing trials are conducted without any 
molecular selection criteria, although many drugs could be probably better tested in a 
molecularly selected population. The knowledge of potential predictive factors for drug 
efficacy in patients with advanced HCC could improve the chance of obtaining positive 
results in clinical trials. 
 
Key-words: hepatocellular carcinoma, clinical trials, regorafenib, ramucirumab, 
cabozantinib, nivolumab.  
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1. INTRODUCTION 
 Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and 
represents the second cause of cancer-related death, causing an estimated number of 
700000 deaths every year [1]. Chronic liver injury and inflammation due to viral or non-viral 
causes are the major etiologies, with the majority of cases occurring in the setting of 
cirrhosis.   
 The Child-Turcotte-Pugh score, that is the most widely used classification for the 
evaluation of underlying hepatic impairment, is commonly applied in clinical practice, 
because hepatic function is associated with prognosis, risk of toxicity and feasibility of the 
different treatment options of HCC patients [2]. Treatment selection for HCC patients is 
guided by the stage of the disease, but in contrast to most solid tumors, where the TNM 
staging system is universally recommended and used, there are several different 
classifications [3]. Among these systems, Barcelona Clinic Liver Cancer (BCLC) staging 
system is the most widely applied, because it has been conceived not only to address 
different prognosis but also to confer a specific therapeutic indication for each stage [4].  
 While local treatments represent standard therapy for HCC patients when the 
disease is diagnosed in early or intermediate stages, the oral multikinase inhibitor 
sorafenib is currently the only approved systemic drug for patients with advanced HCC. 
This agent demonstrated an overall survival benefit within two randomized, placebo-
controlled trials, conducted in both Western and Asian patients eligible for first-line 
treatment [5,6]. The SHARP trial was designed in 2004: at that time, there was no drug of 
proven efficacy for patients with advanced HCC, and placebo was considered an 
acceptable control arm [5]. The SHARP study showed an improvement in survival with the 
administration of sorafenib, extending median overall survival from 7.9 with placebo to 
10.7 months with the experimental drug [Hazard Ratio (HR) 0.69, 95% Confidence Interval 
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(CI) 0.55 – 0.87; p=0.02], with manageable adverse events. In the second randomized 
trial, conducted in Asian subjects, patients receiving sorafenib had a median overall 
survival of 6.5 months, compared with 4.2 months for those receiving placebo [HR 0.68; 
95% CI 0.50–0.93; p=0.014] [6]. As reported above, although the absolute life expectancy  
was longer in the SHARP trial for both study arms compared to the Asian study, the HRs 
for survival were comparable between the two studies. The discrepancy between the 
overall survival in the two control arms may reflect different etiologies and ethnicities 
across two studies, and more advanced disease in Asian-Pacific Study than those in the 
SHARP trial.   
 Following the results of those two trials, sorafenib has been included in international 
guidelines and it represents standard treatment for patients with advanced HCC and well-
preserved liver function (Child-Pugh A). Of note, the evidence about its effectiveness in 
patients with more severe liver impairment is less robust, because Child-Pugh B patients 
were not eligible in both trials. Although sorafenib is widely used in clinical practice in 
Child-Pugh B patients (also due to the lack of effective alternatives), it is not possible to 
robustly define the optimal management of HCC in this clinically relevant subgroup [7-9]. 
 However, even in HCC patients with well preserved liver function, the median life 
expectancy is shorter than 1 year, while the incidence of drug-related adverse events and 
the economic costs are not negligible. This emphasizes the urgent need of developing 
novel medical approaches to improve the outcome of these patients. Interestingly, the 
increasing knowledge of the genomic landscape of HCC and the development of 
molecular targeted therapies represent a promising background for the expansion of the 
number of effective drugs for HCC patients. In recent years, many new drugs have been 
tested in HCC patients as an alternative to sorafenib or after sorafenib failure. In detail, 
first-line trials have compared new drugs as single-agents, or in combination with 
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sorafenib, compared to sorafenib alone, while second-line trials have compared new drugs 
vs. no active treatment (placebo or best supportive care) in patients experiencing 
progressive disease with sorafenib. Unfortunately, to date, none of the first-line trials 
resulted in a positive result. Similarly, with the exception of the trial testing regorafenib 
[10], none of the second-line trials has documented the efficacy of another drug after 
sorafenib failure.   
 Therefore, further research is urgently needed to identify effective strategies to 
improve the prognosis of patients with advanced HCC. In this review, our aim is to 
describe the randomized trials recently conducted in HCC patients, in order to understand 
the main reasons potentially related to these failures. In addition, we briefly describe the 
main ongoing trials, that could potentially change the scenario of HCC treatment in the 
next years. 
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2. Main phase III trials performed in the first-line setting 
 2.1 Sunitinib 
 Sunitinib is an oral multitargeted tyrosine-kinase inhibitor of Vascular Endothelial 
Growth Factor receptor 1 (VEGFR1), VEGFR-2, VEGFR-3, Platelet-Derived Growth Factor 
receptor A (PDGFR-A), PDGFR-B, and several other related tyrosine kinases with anti-
angiogenic and antitumor activity [11]. Differently from sorafenib, however, sunitinib does 
not inhibit Raf-1: this could be potentially relevant, because HCC progression is associated 
with Raf-1/MAP kinase pathway activation, and Raf-1 kinase activity is relevant for HCV 
replication. Before the conduction of a randomized phase III trial in the first-line setting, 
sunitinib had shown antitumor activity in three phase II studies in patients with advanced 
HCC [12-14]. Two of these trials showed a median overall survival in the range of 9 to 10 
months, representing an interesting background for the conduction of a randomized trial 
comparing sunitinib versus sorafenib as first-line treatment. Of note, the phase II trials 
evaluated different doses and schedules of treatment: 37.5 mg/die on a 4 week-on-2 week 
off schedule (schedule 4/2), 50 mg/die on schedule 4/2, or 37.5 mg via continuous daily 
dosing (CDD). In those series of patients, the 50 mg/die schedule 4/2 was associated with 
relevant toxicity (with a non-negligible incidence of treatment-related deaths), while the 
37.5 mg CDD schedule was selected for the phase III trial. The randomized, double-blind, 
phase III study was designed to test if sunitinib was superior (or at least non inferior) to 
sorafenib, in terms of overall survival, in patients with advanced HCC [15]. As detailed in 
Table 1, a total of 1074 patients were randomized. Unfortunately, after an interim analysis, 
the trial was stopped, due to both futility reasons (sunitinib did not meet the criteria to 
demonstrate that it was either superior or non-inferior to sorafenib) and safety reasons 
(higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib 
arm). Disappointingly, although progression-free survival was comparable, overall survival 
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was substantially worse for patients assigned to experimental arm: in detail, median OS 
was 7.9 months for sunitinib arm and 10.2 months for sorafenib arm.  Subgroup analysis 
showed that OS was similar among Asian patients and among HBV-infected patients, but 
was shorter with sunitinib in the subgroup of HCV-infected patients (median OS 9.2 vs 
17.6 months), although the difference was not statistically significant. This difference in 
HCV-infected patients may be related to the specific inhibition of Raf-1 by sorafenib (and 
not by sunitinib); indeed, Raf-1 kinase activity is crucial for HCV replication and this could 
contribute to the efficacy of sorafenib. Despite the non-inferiority hypothesis could be 
considered clinically reasonable when the experimental drug is less toxic than the 
standard one, patients assigned to sunitinib reported more frequent and severe toxicity 
compared to those treated with sorafenib. Of note, treatment-related deaths accounted for 
3.2% of cases in the sunitinib group compared to 0.3% of cases in the sorafenib group. 
Furthermore, grade 3-4 adverse events and temporary treatment discontinuation related to 
adverse events were more frequent in sunitinib group than sorafenib group (82.1% and 
76.6% versus 74.4% and 58.7%, respectively). Based on these completely negative 
results, sunitinib has not been further developed in HCC patients.  
 
 2.2 Brivanib 
 Brivanib is a selective dual inhibitor of fibroblast growth factor receptor (FGFR) and 
VEGF signaling [16]. In a phase II study, designed as a single-arm trial for patients with 
advanced HCC, brivanib was administered orally at a dose of 800 mg once daily [17]. The 
primary endpoint was 6-month progression-free survival, and treatment activity was 
assessed using modified World Health Organization criteria. The 6-month progression-free 
survival rate was 18.2%, median PFS was 2.7 months and median overall survival was 10 
months. Based on this preliminary results, along with the manageable toxicity profile, 
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brivanib was judged worth to be tested as first-line treatment versus sorafenib, within the 
randomized phase III trial Brisk-FL [18]. As shown in Table 1, this phase III study randomly 
assigned 1155 patients to receive sorafenib (at the standard dose of 400 mg twice daily) or 
brivanib (at the same dose tested in the previous phase II study, 800 mg daily). The study 
was designed to test the non-inferiority of brivanib in terms of overall survival. This primary 
end-point was not met: median overall survival in the per-protocol analysis was 9.9 month 
for sorafenib and 9.5 month for brivanib arm (HR = 1.06,  95% CI 0.93 - 1.22; p = 0.311), 
while the prespecified margin for declaring non-inferiority was an upper limit for 95% 
confidence interval less or equal to 1.08. Secondary end-points (TTP, PFS and DCR) were 
similar between the two arms. Similarly to the case of sunitinib, although the study had 
been designed to test the non-inferiority of brivanib, tolerability of the experimental drug 
was worse than sorafenib: most frequent grade 3/4 adverse events were hyponatremia 
(9% vs. 23%, with sorafenib and brivanib respectively), AST elevation (17% vs. 14%), 
fatigue (7% vs. 15%), hand-foot-skin reaction (15% vs. 2%), and hypertension (5% vs. 
13%). Furthermore, discontinuation as a result of adverse events was higher with brivanib 
(43%), than with sorafenib (33%).  
 
 2.3 Linifanib 
 Linifanib is an ATP-competitive inhibitor of all VEGF and PDGF receptor tyrosine 
kinase [19]. In a phase II trial conducted in patients with unresectable or metastatic HCC, 
who had received no more than 1 prior systemic therapy, patients received oral linifanib at 
a dose of 0.25 mg/kg [20]. Primary endpoint of the trial was the progression-free rate at 16 
weeks. The study was conducted mostly in Asian patients (89%), the majority of patients 
(82%) had received no prior systemic treatment, and most patients (86%) had a well 
preserved liver function, with Child-Pugh class A. In this study, linifanib showed promising 
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clinical activity, with a median overall survival of 9.7 months (reaching a median of 10.4 
months in the selected subgroup of patients with Child-Pugh A hepatic function). With all 
the limitations of indirect comparisons, this survival compared favorably with the outcome 
of patients treated with sorafenib in the randomized phase III trial conducted in the Asia-
Pacific region. Based on this background, a randomized phase III trial was designed, to 
compare linifanib versus sorafenib as first-line treatment [21]. Aim of the study was to 
demonstrate the superiority, or at least the non-inferiority, of linifanib compared to 
sorafenib, in terms of overall survival. As shown in Table 1, the study enrolled 1035 
patients, but it did not meet neither the superiority nor the non-inferiority end-point (median 
overall survival was 9.1 months for patients assigned to linifanib vs. 9.8 months for 
patients assigned to sorafenib arm, HR = 1.046, 95% CI 0.896 - 1.22; p=ns). Secondary 
end-point (time to progression and objective response rate) were in favour of linifanib 
(median TTP 5.4 months, ORR 13% with linifanib vs. median TTP 4.0 months and ORR 
6.9% with sorafenib). Again, similarly to what observed with sunitinib and brivanib, despite 
the non-inferiority hypothesis, safety results were in favour of sorafenib: grade 3/4 adverse 
events, serious adverse events, adverse events leading to discontinuation, dose 
interruption, and reduction were significantly more frequent with linifanib. 
 
 2.4 Erlotinib 
 Erlotinib is an oral active, potent elective inhibitor of the EGFR/HER1 related 
tyrosine kinase enzyme, currently used in the treatment of patients with advanced non-
small-cell lung cancer [22]. In two previous phase II trials, erlotinib as a single agent 
showed a modest disease control rate in patients with advanced HCC, and obtained a 
median overall survival of 10 to 13 months [23,24]. In both studies, evaluation of EGFR 
status was performed by immunohistochemistry and the patients was stratified into EGFR 
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high and EGFR low expression cohorts, but there were no significant difference in term of 
overall survival between the high-EGFR and low-EGFR groups. Of note, within a phase I 
trial, the combination of erlotinib plus sorafenib showed promising antitumor activity in 
patients with solid tumors, including hepatocellular carcinoma. Based on these promising 
but scanty data, despite the absence of phase II trials testing the combination of sorafenib 
plus erlotinib in HCC patients, the phase III trial (SEARCH) randomized 720 patients to 
receive the combination vs. sorafenib alone [25]. As reported in Table 1, the study showed 
no significant differences in overall survival (median OS 9.5 months vs. 8.5 months, HR = 
0.929, 95% CI 0.78 - 1.10; p = 0.408). The conclusion of the trial was disappointing: the 
addition of erlotinib did not show any improvement in efficacy, caused an increase in 
adverse events, and caused a reduction in the treatment duration of sorafenib (median 4 
months in the single-agent arm vs. 3 months in the combination arm). 
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3. Phase III trials performed in second-line setting 
 3.1 Brivanib 
 Brivanib has been the first targeted drug tested in a phase III trial in the second-line 
setting of patients with advanced HCC, after disease progression or intolerance with 
sorafenib. In a phase II study, conducted in patients with advanced HCC who had 
progressed after prior anti-angiogenic therapy (mostly sorafenib), brivanib produced an 
objective response rate of 11%, disease control rate equal to 72%, based on post hoc 
analysis using modified Response Evaluation Criteria in Solid Tumors (mRECIST) for 
HCC, and a median overall survival of 9.8 months [26]. Subsequently, the randomized 
phase III trial (BRISK-PS) evaluated the efficacy and safety of brivanib in patients with 
advanced HCC, whose tumor had progressed on/after or who were intolerant to sorafenib 
[27]. As reported in Table 2, the study randomized 395 patients (in a 2:1 ratio) to receive 
brivanib 800 mg/die plus best supportive care or placebo plus best supportive care. 
Brivanib was associated with an improvement in secondary endpoints, such as time to 
progression (4.7 vs. 2.7 months), objective response rate (10% vs. 2%) and disease 
control rate based on mRECIST criteria (61% vs. 40%). Unfortunately, brivanib did not 
significantly improve survival: median overall survival was 9.4 months for patients 
assigned to experimental treatment and 8.2 months with placebo (HR = 0.89, 95% CI 0.69 
- 1.15; p = 0.33). Authors discussed a potential selection bias with an enrichment of 
indolent cases of HCCs (as suggested by the impressive life expectancy of the placebo 
arm), and a potential imbalance in some prognostic factors (particularly portal vein 
invasion) as possible reasons of the negative results.   
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 3.2 Everolimus 
 Everolimus is an oral, selective mTOR (mammalian target of rapamycin) inhibitor 
[28]. This target is a key regulator of cellular growth, proliferation, angiogenesis and 
survival. Furthermore, the mTOR pathway is implicated in hepato-carcinogenesis, with 
activation occurring in up to 45% of HCC and associated with less differentiated tumor and 
poor prognosis. In a phase I/II trial, everolimus demonstrated a disease control rate for at 
least 12 week of 44%, a median time-to-progression of 3.9 months and a median overall 
survival of 8.4 months, with a 10 mg/die schedule [29]. Based on these preliminary results, 
the phase III trial (EVOLVE-1) randomized 546 patients, in a 2:1 ratio, to receive 
everolimus (at the dose of 7.5 mg/die) or placebo as second-line treatment after sorafenib 
failure (Table 2) [30]. No significant difference in overall survival was described between 
the two treatment arms: median overall survival was 7.6 months for patients assigned to 
everolimus and 7.3 months for patients assigned to placebo (Hazard Ratio 1.05, 95% 
confidence interval 0.86 - 1.27; p=0.68). Similarly, time-to-progression was not significantly 
different (median 3.0 months with everolimus vs. 2.6 months with placebo). In a subgroup 
analysis, patients with HBV appeared to have prolonged overall survival with everolimus 
(HR 0.64, 95% CI 0.45-0.93), although it was not clear if this finding could truly represent a 
benefit in this subgroup or rather reflected an imbalance of prognostic factor between 
groups.  
 Based on preclinical evidence suggesting that the combination of everolimus and 
sorafenib could be associated with additive effects, a randomized phase II trial has tested 
the combination of sorafenib and everolimus compared to sorafenib alone, as first-line 
treatment [31]. Primary endpoint of this trial was the progression-free rate at 12 weeks. 
Patients assigned to combination received sorafenib at full dose, combined with 
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everolimus at the dose of 5 mg/die. Unfortunately, no improvement in primary endpoint 
and no suggestion of benefit in other outcomes was shown.   
 
 3.3 Ramucirumab 
 Ramucirumab is a human IgG1 monoclonal antibody that specifically binds with 
high affinity to the extracellular domain of the human Vascular Endothelial Growth Factor 
receptor 2 (VEGFR-2) [32]. Ramucirumab is able to block the interaction of VEGFR-2 with 
its ligand, determining the inhibition of endothelial proliferation and migration. This 
antibody was tested in a phase II study, showing antitumor activity in first-line treatment of 
HCC, with a median PFS of 4.0 month and a promising median overall survival of 12 
months [33]. Of note, in patients with Child-Pugh A cirrhosis, a median OS of 18 months 
was reported. Based on these preliminary, interesting results, a phase III trial (REACH) 
was designed to test the efficacy of ramucirumab [34]. However, although patients enrolled 
in the phase II trial were treatment-naïve, the phase III trial was designed to compare 
ramucirumab versus placebo in the second-line setting, after sorafenib failure. 
Disappointingly, as reported in Table 2, ramucirumab did not significantly improve survival 
over placebo: median overall survival was 9.2 months for patients assigned to 
ramucirumab versus 7.6 months for patients assigned to placebo (Hazard Ratio 0.87, 95% 
confidence interval 0.72-1.05; p=0.14). In subgroup analysis, ramucirumab was associated 
with an improvement in overall survival in patients with high baseline alpha-fetoprotein 
(median overall survival 7.8 months versus 4.2 months, Hazard Ratio 0.67,  95% 
confidence interval 0.51-0.90; p=0.006), while there was no evidence of benefit with 
ramucirumab in patients with low baseline alpha-fetoprotein. As all subgroup analyses, this 
analysis needs further confirmation, that may come from the results of the ongoing phase 
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III trial REACH-2, which is comparing ramucirumab vs placebo in patients with high 
baseline AFP values (see below). 
 
 3.4 Regorafenib  
 Regorafenib is a multi-kinase inhibitor that targets kinases involved in angiogenesis 
(e.g. VEGFR-1–3), oncogenesis (e.g. c-kit, RET and BRAF) and the tumor 
microenvironment (e.g. PDGFR and FGFR) [35]. Regorafenib, at the daily dose of 160 mg, 
was tested in a single-arm phase II study in patients with advanced HCC after failure of 
prior sorafenib therapy [36]. Interestingly, median time-to-progression was 4.3 months, and 
median overall survival was 13.8 months. The most common grade 3/4 adverse events 
included fatigue (17%), hand–foot skin reaction (14%) and diarrhea (6%). Based on these 
data, a phase III randomized controlled trial, the RESORCE [REgorafenib after SORafenib 
in patients with hepatoCEllular carcinoma] study (ClinicalTrials.gov Identifier 
NCT01774344) has been designed [10]. This trial was a double blind, placebo-controlled, 
multicenter phase III study conducted in patients with HCC whose disease had progressed 
after treatment with sorafenib. As detailed in Table 2, the trial enrolled 573 patients, who 
were randomized in a 2:1 ratio to receive either regorafenib (at the standard dose of 160 
mg daily, 3 weeks on / 1 week off) plus best supportive care (BSC) or placebo plus BSC. 
The primary endpoint of the study was overall survival, and secondary efficacy endpoints 
were time to progression, progression-free survival, objective tumor response rate and 
disease control rate. The RESORCE trial met its primary endpoint of a statistically 
significant improvement in overall survival: median overall survival was 10.6 months for 
patients assigned to regorafenib and 7.8 months for patients assigned to placebo. Safety 
profile of regorafenib was similar to what expected with sorafenib: hypertension, hand-foot 
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skin reaction, fatigue and diarrhea were significantly more common in patients assigned to 
regorafenib compared to placebo. 
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4. Main ongoing phase III trials in advanced HCC  
 In this section, we briefly describe selected drugs currently tested in phase III trials 
in patients with advanced HCC. 
 
 4.1 Tivantinib 
 Tivantinib is a non-ATP competitive inhibitor of the tyrosine kinase c-Met, which is 
implicated in cancer cell proliferation, migration, invasion, and metastasis. The c-Met 
receptor is the only known high-affinity receptor for hepatocyte growth factor (HGF), also 
known as scatter factor. Binding of HGF to the c-Met extracellular ligand-binding domain 
results in receptor multimerization and phosphorylation of multiple tyrosine residues in the 
intracellular portion of c-Met. Activation of c-Met results in subsequent activation of signal 
transducers such as PI3K, PLC-γ, STATs, ERK1 and 2, and FAK. N-Methyl-N'-nitro-N-
nitroso-guanidine human steogenic sarcoma cell line transforming protein (gene) (MET) 
gene amplification and/or mutations are found in many human malignancies [37,38].  
 In a phase II randomized controlled study, tivantinib improved PFS in comparison to 
placebo (HR 0.64, 90% CI 0.43 - 0.94; p = 0.04) [39]. Of note, subgroup analysis 
suggested that patients with high MET expression had a significant benefit from tivantinib. 
In detail, median overall survival was 7.2 months (95% CI 3.9 - 14.6) in patients with high 
MET expressing tumors who received tivantinib versus 3.8 months (95% CI 2.1 - 6.8) for 
MET-high patients who were on placebo (HR 0.38, 95% CI 0.18 - 0.81; p = 0.01). 
Following these intriguing results suggested by subgroup analysis, a randomized, placebo-
controlled, double-blind phase 3 study designed to compare tivantinib versus placebo in 
subjects with MET Diagnostic-High (MET-High), advanced HCC has been designed (ARQ 
197-A-U303, ClinicalTrials.gov Identifier NCT01755767). As of June 2016, results are still 
not available. Recently, a second randomized phase III trial has been started, evaluating 
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tivantinib in Japanese patients with c-MET diagnostic-high inoperable HCC 
(ClinicalTrials.gov Identifier NCT02029157).  
 
 4.2 Nivolumab 
 Programmed cell death protein 1 (PD-1) and its ligands, programmed cell death 
ligand 1 (PD-L1) and 2 (PD-L2), play important roles in the regulation of immune 
responses [40]. This inhibitory action might help in immune evasion by cancer cells as PD-
1, PD-L1 and PD-L2 are abnormally expressed by tumor cells and tumor infiltrating 
lymphocytes. Nivolumab and pembrolizumab, both PD-1 antibodies, have been approved 
for advanced melanoma, for advanced non-small cell lung cancer and for an increasing 
number of solid tumors. For HCC, no results have been reported yet. A Phase I/II trial with 
nivolumab in advanced HCC has been designed to produce evidence about tolerability 
and activity of the drug [41]. The first part of this trial was a dose-escalation phase 
designed to establish the safety of the drug at different dose levels for three cohorts: HCC 
patients without viral hepatitis, HCC patients with chronic hepatitis C virus infection and 
HCC patients with chronic hepatitis B virus infection. The second part of the study is an 
expansion phase designed to generate additional clinical data at specified doses for each 
of the three cohorts. Of note, a randomized phase III trial is currently testing the efficacy of 
nivolumab as first-line treatment of patients with HCC: patients assigned to experimental 
arm receive nivolumab, and patients assigned to control arm are treated with sorafenib 
(CheckMate 459: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 459, 
ClinicalTrials.gov Identifier NCT02576509). Primary outcome measures are time-to-
progression and overall survival.  
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 4.3 Ramucirumab  
 As described above, a recent phase III study (REACH) comparing ramucirumab to 
placebo in patients after failure to sorafenib missed its primary end point [34]. The overall 
survival in the intention to treat (ITT) population (n = 565) was not significant different 
between the ramucirumab and the placebo arm (HR 0.866, 95% confidence interval [CI] 
0.717 – 1.046; p = 0.1391; median overall survival 9.2 months for ramucirumab versus 7.6 
months for placebo). However, in the subgroup of patients with baseline AFP ≥ 400 ng/ml 
(n = 250) the overall survival was significantly longer for the patients treated with 
ramucirumab (HR 0.67, 95% CI 0.51 – 0.90; p = 0.0059) with a median overall survival of 
7.8 months for ramucirumab and 4.2 months for placebo. The reason why ramucirumab is 
more active in this situation is not clear, yet. Thus, ramucirumab will be further developed 
in the same population with elevated AFP after failure of sorafenib (either progression or 
intolerance), within the ongoing phase III REACH-2 trial is comparing ramucirumab to 
placebo (ClinicalTrials.gov Identifier NCT02435433). 
 
 4.4 Cabozantinib        
 Cabozantinib is a novel oral multiple tyrosine-kinase targeted agent that can inhibit 
both VEGFR2 and c-Met simultaneously. Cabozantinib can also downregulate KIT, RET, 
FLT3, and Tie-2 [42]. In the trial reported by Cohn et al [43], 41 patients with advanced 
HCC and Child-Pugh class A who received ≤ 1 prior systemic regimen were enrolled. Half 
of them had received prior sorafenib. In the lead-in stage, the patients received 100 mg 
daily over 12 weeks. According to the original RECIST criteria, 2 of 36 patients who were 
evaluable for the tumor assessment at 12 weeks achieved a confirmed partial response. 
The overall disease control rate (partial response + stable disease) at 12 weeks was 68%. 
Based on these results, a randomized phase III trial is currently comparing cabozantinib 
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versus placebo as second-line treatment of patients with advanced HCC (ClinicalTrials.gov 
Identifier NCT01908426).  
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5. Expert commentary: potential reasons for the failure of clinical trials in 
advanced HCC 
The failure of chemotherapy in patients with advanced HCC has been traditionally 
related to the intrinsic resistance of tumor cells to cytotoxic agents, paired with the high risk 
of toxicity in these patients with impaired liver function [44]. After the demonstration of 
efficacy obtained with sorafenib, most clinical oncologists hoped that many “new 
generation” drugs would have proven effective in this setting, rapidly expanding the list of 
treatment options for patients with advanced HCC. Unfortunately, as shown in previous 
paragraphs, this was not the case.  
 A comprehensive analysis of the results obtained in phase III trials conducted in the 
era of targeted agents in HCC patients was recently published [45]. The authors suggest 
that heterogeneity of study populations, lack of understanding of critical drivers of tumor 
progression/dissemination, risk of liver toxicity associated with experimental agents, flaws 
in trial design and marginal antitumoral potency are the main reasons for failure of phase 
III clinical trial on HCC.   
We agree that several reasons have potentially contributed to the failure of recent 
clinical trials [46]. In principle, even if the drug is active and effective, inadequate 
methodology and study design could be the reason for a negative result in a clinical trial. 
Obviously, a study could produce a false negative result if the sample size is too small and 
the statistical power is inadequate to exclude potentially relevant differences between 
treatment arms. However, as shown in Table 1 and Table 2, most trials discussed in 
previous paragraphs were adequately powered to detect clinically relevant differences in 
favor of the experimental treatment.  
Subgroup analyses are commonly conducted to explore the heterogeneity of 
treatment efficacy according to known patients’ characteristics. In some cases, this 
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exploration can suggest the existence of interaction between treatment and a specific 
factor. This was the case for the subgroup analysis of the REACH trial, suggesting a 
significant effect of ramucirumab in patients with high baseline levels of alpha-fetoprotein 
[34]. Of course, subgroup analyses cannot provide definitive evidence (especially when 
they show a positive result in a subgroup within a globally negative trial), but the generated 
hypothesis can be worth to be tested in a prospective trial [47]. 
The adequate sample size of the trial, however, does not “preserve” the study from 
the potential impact of heterogeneity of patients in terms of characteristics and sensitivity 
to experimental drug. From this point of view, one reason substantially contributing to 
failure of new drugs tested in clinical trials is our limited knowledge, if any, about 
biomarkers and predictive factors of drug activity and efficacy. Of note, according to 
current clinical practice guidelines, diagnosis of hepatocellular carcinoma is often based on 
the typical imaging pattern alone, without the need for tissue sample and cytological / 
histological confirmation [48]. Compared to other solid tumors, where the availability of 
tissue is the rule, this reduces the amount of tumor material available for correlative 
studies in the setting of advanced HCC. If this is reasonable for patients receiving standard 
treatment in clinical practice, we strongly believe that tissue collection for patients enrolled 
in clinical trials should be mandatory, in order to allow prospective (or even retrospective) 
correlation of patients’ outcome with specific molecular characteristics. Unfortunately, this 
is not the case for most ongoing clinical trials: in order to describe the proportion of trials 
for patients with advanced HCC including only patients with tissue diagnosis, in 2015 we 
analyzed the description of clinical trials included in the ClinicalTrials.gov registry of the 
U.S. National Institutes of Health, classified as ongoing as of June 2015 (Figure 1). Out of 
69 trials testing experimental drugs in advanced HCC, 40 trials (58%) did not ask for 
cytological / histological diagnosis, that was mandatory in the remaining 29 trials (42%). As 
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expected, most of the ongoing trials are conducted without any molecular selection criteria, 
that was explicit in only 8 trials (12%). This is disappointing, because many drugs could be 
probably better tested in a molecularly selected population. For instance, the exome 
sequencing analysis of 243 liver tumors allowed the identification of 161 putative driver 
genes associated with 11 recurrently altered pathways [49]. The authors emphasized that 
their analysis identified genetic alterations potentially targetable by US Food and Drug 
Administration (FDA)-approved drugs in 28% of the HCCs tested. Given the high 
molecular heterogeneity of advanced HCC, when one of these drugs is tested in 
unselected patients, the activity in the subgroup of potentially sensitive patients could be 
diluted and masked by the absence of activity in the remaining subjects, leading to a 
negative result in the whole study population. The recent history of molecularly targeted 
drugs approved in other solid tumors (for instance, Epidermal Growth Factor receptor or 
ALK tyrosine-kinase inhibitors in advanced non-small cell lung cancer) shows that some 
drugs have a very high activity but in a very limited proportion of patients. Under these 
conditions, biomarker-driven trials are essential for demonstration of benefit and 
subsequent approval. 
Another reason for the failure of potentially active drugs could be the impairment of 
liver function, that is very common in these patients, due to the underlying liver disease. 
This could disappointingly increase the risk of poor tolerability of experimental drugs. In 
order to optimize the development of new drugs in this risky setting of patients, in 2008 an 
International expert panel discussed the methodology of clinical trials in patients with 
hepatocellular carcinoma, stating that experimental drugs should be mostly tested in 
patients with well-preserved liver function (Child-Pugh A) [50]. As emphasized by Llovet 
and colleagues in their position paper, the reason for the exclusion of more impaired liver 
function was that their inclusion would increase the risk of treatment-emergent adverse 
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events and the impact of poor liver function on patients’prognosis, potentially 
compromising the interpretation of results. So it is not surprising that, out of the 69 clinical 
trials included in the ClinicalTrials.gov registry of the U.S. National Institutes of Health 
classified as ongoing as of June 2015, 58 (84%) had  Child-Pugh stage among inclusion 
criteria (Figure 2, Panel A). In detail, the vast majority of trials include only patients with 
well preserved or only slightly impaired liver function: 34 trials for Child A patients only 
(59%) and 12 trials (21%) for Child A and Child B7 patients only (Figure 2, Panel B). This 
restriction should avoid the unintended dilution of treatment activity due to the occurrence 
of toxicity and to the rapid progression of liver failure. However, if we consider the 
unselected population of patients with advanced HCC in the “real-life”clinical practice, 
Child-Pugh A patients represent only a limited proportion of those who are candidates for 
systemic treatment. We must consider that excluding patients with Child-Pugh B from 
frontline drug development will greatly reduce the generalizability of results [51]. However, 
once a drug becomes available in clinical practice, physicians with Child-Pugh B patients 
will face the difficult decision of whether to deny them the new therapy or expose them to 
the risk of unacceptable toxicity against an unconfirmed potential benefit. The story of 
sorafenib represents a good example of the above described risk: both phase 3 trials were 
limited to Child-Pugh A patients [5,6], and no formal demonstration of efficacy is available 
in Child-Pugh B patients, despite the urgent need for effective systemic treatments in 
clinical practice [8].        
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6. Five-year perspective 
 Five years ago, soon after the approval of sorafenib for patients with advanced 
HCC, the majority of experts were relatively sure that one or more drugs that were tested 
in ongoing clinical trials would have shown efficacy and would have subsequently been 
approved for the treatment of patients with advanced HCC. Unfortunately, we now know 
that this was not the case. Regorafenib has been the first drug, after sorafenib, to produce 
a positive result in a phase III trial, while many drugs produced negative results despite the 
interesting background and rationale. 
 This number of failures reminds us that, beyond any good scientific rationale, 
results of clinical trials can be disapponting. Hopefully, in the near future, the knowledge of 
potential predictive factors for drug efficacy in patients with advanced HCC will increase, 
and we are convinced that this could improve the chance of obtaining positive results in 
clinical trials. For instance, we currently do not know if tivantinib will produce a positive 
result in the phase III trial, that is limited to cases with high expression of c-MET, based on 
the hypothesis-generating subgroup analysis of the previous randomized phase II trial [39]. 
However, if the phase III trial will be positive, the development of tivantinib in HCC could 
be a good example of the importance of identifying efficacy biomarkers in the early phases 
of drug development. The risk that a randomized phase III trial could produce a negative 
result despite using an effective drug can be substantially increased if a beneficial effect in 
the proportion of responding patients is “diluted” by a large number of non-responding 
patients [52]. Along with the risk of a false negative result, the other relevant risk, when a 
drug is tested in a phase III trial without sufficient knowledge of predictive factors, is that 
the “dilution” of efficacy produced by the large proportion of non-responding patients can 
determine a statistically significant, but clinically modest improvement. However, the 
identification of molecular biomarkers needs the availability of tumor tissue to be studied. 
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Unfortunately, at the moment, the real issue is the poor availability of tumor tissue in 
patients with HCC compared to other solid tumors. Many efforts are currently made to 
obtain relevant information about tumor molecular profile with “liquid biopsy”, that means 
testing the status of biomarkers in plasma or serum. Probably, in the near future, the role 
of “liquid biopsy” in clinical practice will increase, but currently it cannot be considered a 
substitute of tumor tissue. We strongly recommend that tumor tissue collection should be 
mandatory for patients enrolled in clinical trials.  
 Beyond molecularly targeted agents, immune checkpoint inhibitors represent 
another relevant category of promising drugs, not only in HCC but in all solid tumors. In the 
next five years, the number of tumor types where immune checkpoint inhibitors will prove 
efficacy will rapidly grow. Will HCC be among these cancers? The randomized phase III 
trial comparing nivolumab vs. sorafenib, currently ongoing, will provide evidence about the 
efficacy of this promising anti-tumor strategy. At the beginning of the clinical development 
of nivolumab in this setting, there were many concerns about the tolerability: immune 
response has a role in the severity of chronic hepatitis, and there is a risk of liver toxicity 
when immune-checkpoint inhibitors are administered to patients with HCC. However, 
safety of nivolumab in the phase I-II study was manageable, and it should not represent a 
major obstacle for the use of this drug in HCC patients. To date, we are not able to predict 
if the knowledge about predictive factors of efficacy (for nivolumab as well as for other 
immune-checkpoint inhibitors) will be significantly improved in the near future. At the 
moment, the predictive role of PD-L1 expression on tumor tissue is not clear: coherently, 
the randomized trial is being conducted without any molecular selection for the eligibility of 
patients.  
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7. Key issues 
 Regorafenib has been the first drug, after sorafenib, to produce a positive result in a 
phase III trial conducted in patients with advanced hepatocellular carcinoma, while 
many drugs produced negative results despite the interesting background and 
rationale. 
 Heterogeneity of study populations, lack of understanding of critical drivers of tumor 
progression/dissemination, risk of liver toxicity associated with experimental agents, 
flaws in trial design and marginal antitumoral potency can be considered the main 
reasons for failure of phase III clinical trials in HCC.   
 Most of the ongoing trials are conducted without any molecular selection criteria. This 
is disappointing, because many drugs could be probably better tested in a molecularly 
selected population. 
 Hopefully, in the near future, the knowledge of potential predictive factors for drug 
efficacy in patients with advanced HCC will increase, and this could improve the 
chance of obtaining positive results in clinical trials. 
 The randomized phase III trial comparing nivolumab vs. sorafenib, that is currently 
ongoing, will provide evidence about the efficacy of the immune checkpoint inhibition 
strategy in advanced HCC. 
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Figure legends 
Figure 1. Characteristics of clinical trials for patients with advanced hepatocellular 
carcinoma, ongoing as of June 2015. Panel A: absence or presence of cyto/histological 
diagnosis among eligibility criteria. Panel B: absence or presence of molecular selection 
among eligibility criteria. Source: ClinicalTrials.gov registry of the U.S. National Institutes of 
Health, www.clinicaltrials.gov   
Figure 2. Characteristics of clinical trials for patients with advanced hepatocellular 
carcinoma, ongoing as of June 2015. Panel A: number of trials allowing inclusion of each 
Child-Pugh category, out of 58 trials with information available. Panel B: distribution of 
trials according to Child-Pugh category eligible for inclusion. Source: ClinicalTrials.gov 
registry of the U.S. National Institutes of Health, www.clinicaltrials.gov   
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